Project Grant HT94252410414
Award Date
5/15/24
Completion Date
5/14/26
Dollars Obligated
$682K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
The Defense Health Agency has awarded a $1,683,194 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, effective from August 1, 2025 to July 31, 2028, will fund research focused on the role of the glycome in TSC biomarker identification and molecular pathogenesis. Brigham & Women's Hospital Inc., a prominent academic medical center and research institution affiliated with Harvard Medical...
The Defense Health Agency awarded a $1,318,799.00 Project Grant to Brigham & Women's Hospital Inc. in Boston, MA on June 15, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "THE BRIDGE PROJECT: BROADENING THE REACH OF IMAGING, DIAGNOSTICS, AND GENETIC EVALUATION", will fund research and development to transform healthcare for U.S. military service members and the public through innovative medical solutions for the battlefield and...
Brigham & Women's Hospital Inc. was awarded a $379,876 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2023 through August 31, 2026 to investigate whether microbiome-derived cell fragments in the brain can accelerate the transition from traumatic brain injury to Alzheimer's disease or related dementias. As the direct awardee, Brigham & Women's Hospital will leverage...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $566,810.00 to Brigham & Women's Hospital Inc., a non-profit hospital and research institution in Boston, MA, to support research on the neural regulation of small cell lung cancer progression. The award period is from September 1, 2023 to August 31, 2025. Brigham & Women's Hospital Inc. has previously conducted biomedical research and provided...
The federal Project Grant award of $644,400 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital Inc. to optimize anti-PD1-based therapy for metastatic renal cell carcinoma. The research aims to transform healthcare for military service members and the general public by advancing innovative approaches to disease prevention, diagnosis, and treatment. The research will be conducted at...
The U.S. Defense Health Agency awarded Brigham & Women's Hospital Inc. a $653,343 Project Grant under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to identify novel therapeutic strategies for chromophobe renal cell carcinoma. The three-year project, with a period of performance from Sep 30, 2023 to Sep 29, 2026, will focus on basic and applied biomedical research to develop innovative treatments for this rare form of kidney cancer. As a...
Brigham & Women's Hospital Inc. was awarded a $596,016 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 1, 2023 to August 31, 2027 to investigate environmental and gut-brain axis determinants of cognitive outcomes in Parkinson's disease. As the primary awardee, Brigham & Women's Hospital will leverage its expertise in biomedical research and healthcare services...
The U.S. Defense Health Agency awarded a $538,596 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "IDENTIFICATION OF THE LIVER MICROENVIRONMENT THAT DRIVES UVEAL MELANOMA METASTASIS AND IMMUNITY". The project aims to advance scientific understanding of the liver microenvironment and how it contributes to the metastasis and immune response related to uveal melanoma, a rare and...
The U.S. Defense Health Agency (DHA) awarded a $409,792 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated. The grant, with a performance period from March 2025 to March 2027, supports research on a "Highly Penetrating Nanodisc for Targeting Fibroblast Plasticity in Pulmonary Fibrosis." This cutting-edge medical research aims to develop innovative...
The Defense Health Agency awarded Brigham & Women's Hospital Inc. a $253,636 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2025 to investigate the role of the secreted factor CTHRC1 in the pathogenesis of tuberous sclerosis complex. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care...